연구
교육
솔루션
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
School of Pharmaceutical Sciences,
Center for Cellular & Structural Biology
Jiayu Liu has not added Biography.
If you are Jiayu Liu and would like to personalize this page please email our Author Liaison for assistance.
A targeted IL-15 fusion protein with potent anti-tumor activity.
Cancer biology & therapy , 2015 | Pubmed ID: 26176990
BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.
Translational oncology Oct, 2017 | Pubmed ID: 28797938
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Journal of immunotherapy (Hagerstown, Md. : 1997) Jan, 2018 | Pubmed ID: 29232309
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
PloS one , 2018 | Pubmed ID: 29357376
A Single Domain-Based Anti-Her2 Antibody Has Potent Antitumor Activities.
Translational oncology Apr, 2018 | Pubmed ID: 29455083
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
International journal of nanomedicine , 2018 | Pubmed ID: 29881272
A HER2 bispecific antibody can be efficiently expressed in with potent cytotoxicity.
Oncology letters Jul, 2018 | Pubmed ID: 29963199
Sun Yat-sen University
Yanlan Wang1,2,
Jiayu Liu1,2,
Haitao Pan1,2,
Jieyu Xing1,2,
Xiaoqiong Wu1,2,
Qing Li1,2,
Zhong Wang1,2
1School of Pharmaceutical Sciences, Sun Yat-Sen University,
2Center for Cellular & Structural Biology, Sun Yat-Sen University
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유